XML 18 R9.htm IDEA: XBRL DOCUMENT
v3.23.1

JT Pharmaceuticals Asset Purchase Agreement | 12 Months Ended
--- | ---
Dec. 31, 2022
Jt Pharmaceuticals Asset Purchase Agreement |
JT Pharmaceuticals Asset Purchase Agreement |
| 3. | JT Pharmaceuticals Asset Purchase Agreement
In October 2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma’s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with our ProNeura long-term, continuous drug delivery technology, for the treatment of chronic pruritus and other medical conditions. Under the terms of the JT Agreement, JT Pharma received a $15,000 closing payment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of certain developmental and regulatory milestones, and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization. In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $100,000 and issued 51,021 shares of our common stock to JT Pharma. The related expense was included in research and development expenses in our statements of operations.

X
- References No definition available. + Details
Name: | ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract
Namespace Prefix: | ttnp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock
Namespace Prefix: | ttnp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration